日本語
日本語
日本語
Therabest Japan Inc. is a company endeavoring to create advanced fusion therapeutics by combining innovative new drugs with cell-based therapies to treat intractable diseases.

Mission Statement

Therabest Japan is dedicated to combining innovative biotechnology to create therapies that can improve the lives of many people by combating complex diseases.

Message from CEO

Therabest Japan Inc. is a research based pharmaceutical company that develops iPSC-derived cell therapies. There are many patients in the world who suffer from intractable diseases. One of our goals is to provide innovative treatment opportunities to those patients through our iPSC-derived cell therapy platform. We will also improve their quality of life by restoring patients’ immune systems to help them return to their daily lives. We will further advance our iPSC-derived cell therapy platform technology and pioneer the development of leading therapeutics through in-depth research and continual iteration of our technology.

About Therabest Japan

Therabest Japan is a biotechnology company combining expertise in induced Pluripotent Stem Cell (iPSC) technology, immunology, genome engineering, Extracellular Vesicles, and biomanufacturing to develop bioengineered off-the-shelf cell and extracellular vesicle therapies for oncology and regenerative medicine applications.
Therabest Japan is a subsidiary of Therabest, a Korean biopharma company that has developed enhanced iPSC-derived Natural Killer cell therapies to target diverse cancer types and treat immunological diseases. Therabest is headquartered in Seoul and has established a dedicated GMP production facility in Seoul.

What's New

Technology

Using induced Pluripotent Stem Cell (iPSC) technology, Therabest Japan is developing iPSC-derived cell therapy products, as well as iPSC-derived cell and organoid platforms for Extracellular Vesicle (EV) research. By utilizing gene editing in iPSCs, Extracellular Vesicles can be engineered to have enhanced potency and specificity. The goal of this work is to develop specialized, off-the-shelf EV therapeutics for use in cancer therapy and regenerative medicine.

Management

01
Co-CEO
Koichi Seriu, LLM

Education:
Tsukuba University, LL.M (Antitrust Law).

Worked for:
Nippon Boehringer Ingelheim Co., Ltd. Associate General Counsel

02
Co-CEO
Shin-Il Kim, Ph.D

Education:
University of Wisconsin-Madison, Ph.D (Molecular biology)

Worked for:
University of California-San Francisco, Postdoctoral fellow
Center for iPS Cell Research and Application (CiRA), Kyoto University, Assistant Professor
aceRNA Technologies Co., Ltd, CSO Director, Division of R & D

03
CSO
Nicholas Boyd-Gibbins, Ph.D

Education:
University College London, Ph.D (Sensory Neuroscience)

Worked for:
Kyoto University CiRA, Postdoc
Stem Cells 21, Thailand, Head of Research

進照夫3
COO
Teruo Susumu, Ph.D

Education:
Kyushu University, School of Science

Worked for:
Fujisawa Pharmaceutical Co., Ltd. (curt. Astellas Pharma Inc.)
Shin Nippon Biomedical Laboratories, LTD
BioFrontier Partners Inc
aceRNA Technologies Co., Ltd., President (until May 26th, 2022)

About Us

Therabest Japan Inc.

  • CEOs: Shin-Il Kim, Koichi Seriu
  • Capital fund: JPY28,000,000-
  • Established: February 14, 2022
  • Address: CLIK 211, 6-3-7, Minatojima-Minamimachi, Chuo-ku,
    Kobe city, Hyogo, Japan 〒650-0047
image004
  • Monday - Friday 9:00am - 5:00pm
Facebook-f Twitter Instagram

©All Rights Reserved by Therabest Japan Inc.